Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

Phase 3

Active, not recruiting

Conditions: Hemophilia A

Interventions: Biological: Adynovate

First Posted Date: 2023-01-31

Last Posted Date: 2024-07-08

Lead Sponsor: Takeda

Target Recruit Count: 37

Registration Number: NCT05707351

Locations: 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, China
🇨🇳
Beijing Children's Hospital, Capital Medical University, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China

and more 9 locations

A Study Measuring Substances Potentially Indicating Bone Problems in Adults With Type 1 Gaucher Condition

Completed

Conditions: Gaucher Disease

Interventions: Other: No Intervention

First Posted Date: 2023-01-27

Last Posted Date: 2024-12-11

Lead Sponsor: Takeda

Target Recruit Count: 125

Registration Number: NCT05702814

Locations: 🇪🇸
Fundación Española para el Estudio y Tratamiento de la Enfermedad de Gaucher (FEETEG), Zaragoza, Aragon, Spain

A Survey to Describe the Experience and Unmet Needs of Persons Living With Von Willebrand Disease (VWD) and Their Caregivers

Completed

Conditions: Von Willebrand Disease (VWD)

Interventions: Other: No Intervention

First Posted Date: 2023-01-25

Last Posted Date: 2023-12-20

Lead Sponsor: Takeda

Target Recruit Count: 12

Registration Number: NCT05695560

Locations: 🇨🇦
YolaRx Consultants, Montreal, Canada

A Study of TAK-861 in Participants With Narcolepsy Type 1

Phase 2

Completed

Conditions: Narcolepsy Type 1

Interventions: Drug: Placebo
Drug: TAK-861

First Posted Date: 2023-01-18

Last Posted Date: 2025-01-09

Lead Sponsor: Takeda

Target Recruit Count: 112

Registration Number: NCT05687903

Locations: 🇦🇺
Woolcock Institute of Medical Research, Sleep and Circadian Research Group, Glebe, New South Wales, Australia
🇯🇵
Kurume University Hospital, Kurume-Shi, Hukuoka, Japan
🇯🇵
Koishikawa Tokyo Hospital, Bunkyo-Ku, Tokyo, Japan

and more 54 locations

A Study of TAK-861 in Participants With Narcolepsy Type 2

Phase 2

Completed

Conditions: Narcolepsy Type 2

Interventions: Drug: Placebo
Drug: TAK-861 2 mg
Drug: TAK-861 2 mg and 5 mg

First Posted Date: 2023-01-18

Last Posted Date: 2025-01-09

Lead Sponsor: Takeda

Target Recruit Count: 71

Registration Number: NCT05687916

Locations: 🇺🇸
SDS Clinical Trials, Inc., Santa Ana, California, United States
🇺🇸
Ohio Sleep Medicine Institute, Dublin, Ohio, United States
🇺🇸
Stanford Center for Sleep Sciences and Medicine, Redwood City, California, United States

and more 53 locations

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Phase 3

Recruiting

Conditions: Alpha1-Antitrypsin Deficiency

Interventions: Other: Placebo
Drug: Fazirsiran Injection

First Posted Date: 2023-01-10

Last Posted Date: 2024-12-30

Lead Sponsor: Takeda

Target Recruit Count: 160

Registration Number: NCT05677971

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States

and more 66 locations

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Phase 2

Recruiting

Conditions: Lymphoma

Interventions: Drug: Brentuximab Vedotin
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone

First Posted Date: 2023-01-06

Last Posted Date: 2024-02-16

Lead Sponsor: Takeda

Target Recruit Count: 52

Registration Number: NCT05673785

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
Chongqing University Cancer Hospital, Chongqing, China
🇨🇳
The First Affiliated Hospital of Zhejiang University school of medicine, Hangzhou, China

and more 13 locations

A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home Infusion

Not yet recruiting

Conditions: Gaucher Disease

First Posted Date: 2023-01-03

Last Posted Date: 2024-03-12

Lead Sponsor: Takeda

Target Recruit Count: 60

Registration Number: NCT05669729

A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil

Recruiting

Conditions: Crohn's Disease
Ulcerative Colitis

Interventions: Other: No Intervention

First Posted Date: 2022-11-23

Last Posted Date: 2025-01-09

Lead Sponsor: Takeda

Target Recruit Count: 2160

Registration Number: NCT05626088

Locations: 🇧🇷
Pesquisare Saúde S/S Ltda, Santo André, São Paulo, Brazil

A Study of Soticlestat in Healthy Adult Nondependent Recreational Drug Users With Central Nervous System (CNS) Depressant Experience

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Soticlestat 300 mg
Drug: Soticlestat 600 mg
Drug: Soticlestat 900 mg
Drug: Alprazolam
Drug: Placebo

First Posted Date: 2022-11-02

Last Posted Date: 2024-12-09

Lead Sponsor: Takeda

Target Recruit Count: 100

Registration Number: NCT05602818

Locations: 🇺🇸
Altasciences, Overland Park, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy